Work-up and management of a high-risk patient with primary central nervous system lymphoma

References

1. 1.↵
   2. Ferreri AJM.

   How I treat primary CNS lymphoma. Blood. 2011; 118(3): 510–22.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Villano JL,
   3. Koshy M,
   4. Shaikh H,
   5. Dolecek TA,
   6. McCarthy BJ.

   Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011; 105: 1414–8.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Camilleri-Broët S,
   3. Martin A,
   4. Moreau A,
   5. Angonin R,
   6. Hénin D,
   7. Gontier MF, et al.

   Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998; 110: 607–12.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Campo E,
   3. Swerdlow SH,
   4. Harris NL,
   5. Pileri S,
   6. Stein H,
   7. Jaffe ES.

   The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117: 5019–32.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Chen D,
   3. Gu W,
   4. Li W,
   5. Liu X,
   6. Yang X.

   Primary diffuse large B-cell lymphoma of the central nervous system: a case report and literature review. Oncol Lett. 2016; 11: 3085–90.

   OpenUrl
6. 6.↵
   2. Ferreri AJM,
   3. Marturano E.

   Primary CNS lymphoma. Best Pract Res Clin Haematol. 2012; 25: 119–30.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Mrugala MM,
   3. Rubenstein JL,
   4. Ponzoni M,
   5. Batchelor TT.

   Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep. 2009; 11: 73–80.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Bessell EM,
   3. Hoang-Xuan K,
   4. Ferreri AJM,
   5. Reni M.

   Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer. 2007; 43: 1141–52.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   2. Ferreri AJM,
   3. Reni M,
   4. Foppoli M,
   5. Martelli M,
   6. Pangalis GA,
   7. Frezzato M, et al.

   High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374: 1512–20.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Ferreri AJ,
    3. Cwynarski K,
    4. Pulczynski E,
    5. Ponzoni M,
    6. Deckert M,
    7. Politi LS, et al.

    Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3: e217–27.

    OpenUrl
11. 11.↵
    2. Fischer L,
    3. Jahnke K,
    4. Martus P,
    5. Weller M,
    6. Thiel E,
    7. Korfel A.

    The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. Haematologica. 2006; 91: 429–30.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Bromberg JEC,
    3. Breems DA,
    4. Kraan J,
    5. Bikker G,
    6. van der Holt B,
    7. Smitt PS, et al.

    CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007; 68: 1674–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    2. Canovi S,
    3. Campioli D.

    Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: a systematic review. Diagn Cytopathol. 2016; 44: 841–56.

    OpenUrl